Neurocrine Biosciences (NBIX) Free Cash Flow (2010 - 2026)

Neurocrine Biosciences' Free Cash Flow history runs 17 years deep, the most recent figure standing at $144.4 million for Q1 2026.

• Quarterly Free Cash Flow rose 166.91% year-over-year to $144.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $839.0 million (up 70.46% YoY) and the FY2025 annual result came in at $748.7 million, up 34.37% from the prior year.
• Free Cash Flow was $144.4 million for Q1 2026 at Neurocrine Biosciences, down from $390.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $390.8 million in Q4 2025 and bottomed at -$125.8 million in Q1 2023.
• A 5-year average of $128.0 million and a median of $140.0 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow soared 3440.43% — and 2023, when it sank 190.53%.
• Neurocrine Biosciences' Free Cash Flow stood at $157.0 million in 2022, then fell by 22.36% to $121.9 million in 2023, then surged by 68.25% to $205.1 million in 2024, then soared by 90.54% to $390.8 million in 2025, then slumped by 63.05% to $144.4 million in 2026.
• Business Quant data shows NBIX's Free Cash Flow at $144.4 million in Q1 2026, $390.8 million in Q4 2025, and $193.0 million in Q3 2025.